Biomea Fusion Inc. Common Stock (BMEA)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable earnings and a margin of safety. Biomea Fusion does not fit that mold today. It is a clinical-stage diabetes and obesity company with 37 employees and no reported revenue in the filed figures. In fiscal year 2023, ended 2023-12-31, net loss was $117.3 million; in fiscal year 2024, ended 2024-12-31, net loss was $138.4 million; and in fiscal year 2025, ended 2025-12-31, net loss was $61.8 million. The trend improved further in fiscal Q1 2026, the quarter ended 2026-03-31, with a $12.4 million net loss, and in fiscal Q2 2026, the quarter ended 2026-06-30, with an $8.3 million net loss. Still, trailing free cash flow is negative $47.2 million, a negative 51.7% FCF yield on a $91.3 million market cap. The financial-strength signals are weak: a Piotroski F-Score of 1/9 and an Altman Z-Score of -14.78, both FairStock calculations. Debt is low at D/E 0.07, but ROE is -164.14% and ROCE is -63.46%. At the 2026-10-13 close of $1.26, P/B is 7.41 and P/E is -7.00. There is no meaningful moat yet; any durability must come from clinical data, patents, and regulatory approval, not current financials. The FairStock Score is 52/100, and the Lynch category is none because losses occurred in each of the last four years. This is a pipeline lottery ticket, not a Graham bargain.

In plain English: Biomea Fusion is a small healthcare company working on oral medicines for diabetes and obesity. It has no product sales and has lost money in each of the last four years, so the business currently looks weak and unproven. At $1.26 a share, the price does not look cheap based on today's financial results; it mostly reflects hope that its drug trials will succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer